Completed PHASE3 INTERVENTIONAL 2-arm NCT00277641

Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity

Lamotrigine in the Treatment of Binge Eating Disorder Associated With Obesity: A Single-Center, Double-Blind, Placebo-Controlled, Flexible-Dose Study in Outpatients

Sponsor: GlaxoSmithKline

Conditions Binge Eating Disorder Obesity

Interventions Lamotrigine placebo

Updated 5 times since 2017 Last updated: Jun 21, 2011 Started: Mar 31, 2006 Primary completion: Jan 31, 2009 Completion: Jan 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Binge Eating Disorder and Obesity and is currently completed. GlaxoSmithKline leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Lindner Center of HOPE
University of Cincinnati

Data source: Lindner Center of HOPE

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mason, United States